Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).

被引：2

作者：

Palmero, Lorenza

Mazzeo, Roberta

Buriolla, Silvia

Allegri, Lorenzo

Bortot, Lucia

Franzoni, Alessandra

Michelotti, Anna

Stefani, Elisabetta Camilla

Turra, Giulia

Zilli, Miriam

Di Nardo, Paola

Roncato, Rossana

Bonotto, Marta

Cecchin, Erika

Belletti, Barbara

Toffoli, Giuseppe

Gerratana, Lorenzo

Baldassarre, Gustavo

Damante, Giuseppe

Puglisi, Fabio

机构：

[1] Univ Udine, Dept Med Area, Udine, Italy

[2] Dept Med Oncol, IRCCS, CRO Aviano, Udine, Italy

[3] Univ Udine, Dept Med DAME, Udine, Italy

[4] Azienda Sanitaria Univ Friuli Cent ASUFC, Inst Human Genet, Udine, Italy

[5] Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Med, IRCCS, Aviano, Italy

[6] Ctr Riferimento Oncolog Aviano CRO, Clin & Expt Pharmacol, IRCCS, Aviano, Italy

[7] Univ Hosp Udine, Dept Oncol, Udine, Italy

[8] CRO Natl Canc Inst, Aviano, Italy

[9] Ctr Riferimento Oncol Aviano CRO, Unit Mol Oncol, IRCCS, Aviano, Italy

[10] Natl Canc Inst, Expt & Clin Pharmacol, Aviano, Italy

[11] Northwestern Univ, Feinberg Sch Med, Dept Med Hematol & Oncol, Evanston, IL USA

[12] Univ Udine, Dept Med DAME, Chicago, IL USA

[13] Ctr Riferimento Oncol Aviano CRO, Unit Mol Oncol, IRCCS, I-33081 Aviano, Italy

[14] Univ Udine, Azienda Sanitaria Univ Friuli Cent ASUFC Udine, Inst Human Genet, Udine, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.1027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1027

引用

页数：3

共 50 条

[31] Increased risk of vertebral fractures in healthy bone in metastatic breast cancer patients treated with CDK4/6 inhibitors combined with endocrine therapy
Bergamini, M.
Pedersini, R.
Brentegani, C.
Baluta, V.
Schivardi, G.
Cosentini, D.
di Mauro, P.
Zamparini, M.
Lagana, M.
Amoroso, V.
Vassalli, L.
Alberti, A.
Laini, L.
Simoncini, E. L.
Berruti, A.
ANNALS OF ONCOLOGY, 2023, 34 : S378 - S379
[32] Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors
Kapagan, Tanju
Bulut, Nilufer
Erdem, Gokmen Umut
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (08) : 1403 - 1410
[33] TREATMENT PATTERNS INCLUDING ADHERENCE/PERSISTENCE WITH CYCLIN-DEPENDENT KINASE 4&6 INHIBITORS (CDK4&6I) AMONG US COMMERCIALLY INSURED WOMEN WITH METASTATIC BREAST CANCER (MBC)
Singhal, M.
Nepal, B.
Fisch, M. J.
Debono, D.
Grabner, M.
Stephenson, J. J.
Churchill, C.
Gable, J.
Zhu, Y.
Stenger, K.
Carter, Cuyun G.
VALUE IN HEALTH, 2020, 23 : S462 - S462
[34] Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors
Kubilay Tolunay, Pinar
Kurt Inci, Bediz
Usta, Sura
Topkac, Ali
Karabuga, Berkan
Aydemir, Ergin
Oner, Irem
Akay Hacan, Busra
Ates, Ozturk
Karacin, Cengiz
Yalcintas Arslan, Ulku
CURRENT ONCOLOGY, 2024, 31 (12) : 7426 - 7436
[35] Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i)
Martinez-Saez, O.
Pascual, T.
Braso-Maristany, F.
Chic, N.
Gonzalez-Farre, B.
Sanfeliu, E.
Rodriguez, A.
Martinez, D.
Galvan, P.
Rodriguez Hernandez, A.
Schettini, F.
Conte, B.
Vidal, M. J.
Adamo, B.
Munoz, M.
Moreno, R.
Ciruelos, E. M.
Faull, I.
Odegaard, J.
Prat, A.
ANNALS OF ONCOLOGY, 2020, 31 : S17 - S17
[36] Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
Wander, Seth Andrew
Weipert, Caroline M.
Liao, Jiemin
Safonov, Anton
Zhang, Nicole
Bardia, Aditya
Razavi, Pedram
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group
Fountzilas, Elena
Koliou, Georgia-Angeliki
Vozikis, Athanassios
Rapti, Vassiliki
Nikolakopoulos, Achilleas
Boutis, Anastasios
Christopoulou, Athina
Kontogiorgos, Ioannis
Karageorgopoulou, Sofia
Lalla, Efthalia
Tryfonopoulos, Dimitrios
Boukovinas, Ioannis
Rapti, Cleopatra
Nikolaidi, Adamantia
Karteri, Sofia
Moirogiorgou, Evangelia
Binas, Ioannis
Mauri, Davide
Aravantinos, Gerasimos
Zagouri, Flora
Saridaki, Zacharenia
Psyrri, Amanda
Bafaloukos, Dimitrios
Koumarianou, Anna
Res, Eleni
Linardou, Helena
Mountzios, Giannis
Razis, Evangelia
Fountzilas, George
Koumakis, Georgios
ESMO OPEN, 2020, 5 (04)
[38] The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting
Kubeczko, Marcin
Polakiewicz-Gilowska, Anna
D'Amico, Andrea
Chrabanski, Olgierd
Swiderska, Katarzyna
Chmielik, Ewa
Blamek, Slawomir
Handkiewicz-Junak, Daria
Jarzab, Michal
FRONTIERS IN ONCOLOGY, 2024, 14
[39] Trilaciclib hydrochloride Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor Myelopreservation therapy Treatment of small cell lung cancer Treatment of triple-negative breast cancer
Barquero, N.
DRUGS OF THE FUTURE, 2020, 45 (02) : 99 - 107
[40] Efficacy and toxicity of endocrine therapy plus cyclin-dependent kinases 4/6 inhibitors (iCDK4/6) in metastatic breast cancer patients according to gBRCA status
Bruno, L. I.
Costanzo, M. V.
Ostinelli, C. A.
Nervo, A. A.
Nadal, J.
Colo, F.
Loza, J.
Loza, C. M.
Ponce, C.
Fabiano, V.
Blanco, A. G.
Perez de la Puente, C.
Chacon, R. D.
ANNALS OF ONCOLOGY, 2018, 29 : 98 - 98

← 1 2 3 4 5 →